Results 191 to 200 of about 46,198 (239)
Some of the next articles are maybe not open access.

Advances in the use of hydroxyurea

Hematology, 2009
Abstract Clinical experience with hydroxyurea for patients with sickle cell disease (SCD) has been accumulating for the past 25 years. The bulk of the current evidence suggests that hydroxyurea is well-tolerated, safe, and efficacious for most patients with SCD.
Russell E, Ware, Banu, Aygun
openaire   +2 more sources

Pharmacokinetics and Pharmacodynamics of Hydroxyurea

Clinical Pharmacokinetics, 1998
Hydroxyurea is used in the treatment of various forms of cancer, sickle-cell anaemia and HIV infection. Oral absorption of the drug is virtually complete, the volume of distribution is equivalent to total body water and elimination is through both renal and nonrenal mechanisms.
P R, Gwilt, W G, Tracewell
openaire   +2 more sources

Hydroxyurea: Mechanism of Action

Science, 1963
Acetohydroxamic acid has been identified, by paper chromatography, in the blood of three patients with chronic myelogenous leukemia on hydroxyurea therapy. This suggests that the drug is hydrolyzed yielding hyroxylamine, which then cleaves thioesters, in particular acetyl-coenzyme A.
W N, FISHBEIN, P P, CARBONE
openaire   +2 more sources

Hydroxyurea Administered Intermittently

JAMA: The Journal of the American Medical Association, 1965
THE SYNTHESIS of hydroxyurea (Hydrea) was reported in 1869 by Dresler and Stein. 1 In animal studies, Rosenthal et al 2 found that the compound produced anemia, severe leukopenia, and megaloblastic changes in the peripheral blood and bone marrow. Recently, this compound has been introduced into cancer chemotherapy. Tumor responses have been observed in
H J, LERNER, G L, BECKLOFF
openaire   +2 more sources

HYDROXYUREA INDUCED HEPATITIS

Medical Journal of Australia, 1980
A case of hydroxyurea-induced self-limited hepatitis with an influenza-like reaction to hydroxyurea therapy is presented. The association was supported by recurrence of the symptoms on rechallenge with the drug.
R, Heddle, A F, Calvert
openaire   +2 more sources

Inhibition of urease by hydroxyurea

Biochemical Pharmacology, 1965
Abstract Hydroxyurea was shown to be a potent inhibitor of urease; 50% inhibition occurred at a concentration of approximately 5 × 10−5 M. Preincubation of the enzyme with the inhibitor prior to addition of substrate yielded inhibition which progressed with time, whereas simultaneous addition of inhibitor and substrate to the enzyme reduced the ...
openaire   +2 more sources

Excretion of hydroxyurea into milk

Cancer, 1987
This article documents that hydroxyurea (HUR) is excreted into human breast milk, and it reviews the literature describing similar evaluations for other antineoplastic agents.
R K, Sylvester   +4 more
openaire   +2 more sources

Hydroxyurea and Bronchogenic Carcinoma

Australasian Radiology, 1974
SUMMARYThe disappointing outlook in the treatment and prognosis of lung cancer still continues and is an enigma which baffles clinicians in the management of this disease.A selected clinical trial was carried out in the Royal Adelaide Hospital using hydroxyurea and irradiation in one group of patients versus a placebo group who received irradiation ...
openaire   +2 more sources

Psoriasis and Hydroxyurea

British Journal of Dermatology, 1972
R, Touraine, J, Revuz, M, Tulliez
openaire   +2 more sources

Hydroxyurea and infected stones

Urology, 1978
The formation of struvite stones is closely linked to the enzyme urease produced by certain bacteria found in urine. It has been shown that hydroxamic acids will block the activity of this enzyme. One of these, hydroxyurea, in a morning dose of 500 mg. was used in 21 patients for three months or longer.
openaire   +2 more sources

Home - About - Disclaimer - Privacy